Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (PEG)-BHD1028

NCT06563115 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Insulin Resistance

Interventions

DRUG: (PEG)-BHD1028 Single Ascending Dose
DRUG: (PEG)-BHD1028 Multiple Ascending Dose
OTHER: Placebo

Sponsor

EncuraGen, Inc